PHILADELPHIA, April 18, 2015 /PRNewswire/ --
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the American Associate of Cancer Research Annual Meeting (April 18-22 in Philadelphia, PA).
(Logo: http://photos.prnewswire.com/prnh/20130418/608115)
Aurigene will present data for its proprietary Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors program, which is currently in preclinical development.
Aurigene and Curis will present data from their interleukin-1 receptor association kinase-4, or IRAK-4, inhibitor program.
Help employers find you! Check out all the jobs and post your resume.
